Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of ...

Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA ...

The Garden State is looking to grow into the next big biotech hub. | The Garden State is looking to grow into the next big ...

WASHINGTON — FDA Commissioner Martin Makary offered more details into the agency’s recently announced plans to place ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

In its yearly survey of international clinicians and patients, Philips illustrated significant gaps in people’s trust when it ...

RA Ventures, also known as Raven, is a healthcare accelerator for the prominent life sciences venture capital firm. The ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Medtech association AdvaMed went to Capitol Hill today to make the case that the medical device industry should be exempt ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...